Bio

on also acquired the name EUSA Pharma from Jazz Pharmaceuticals and has built EUSA Pharma “II” into one of the fastest growing Fund 1 portfolio companies, which was acquired by Recordati in March 2022. Prior to founding the original EUSA Pharma, Mr. Morton started Zeneus Pharma through the purchase of Elan’s European business for $120 million and served as the company’s CEO. Zeneus was acquired two years later by Cephalon following a period of rapid revenue and EBITDA growth. Recently Mr Morton has founded two biopharmaceutical companies, Izana Bio and Akaza Bio. Izana was recently sold and Akaza is developing a drug candidate in Acute Liver Disease based on a license of a TLR4 drug from Takeda. Previously, Mr. Morton held several senior executive positions in the United States, the UK, Belgium and Australia with Merck & Co Inc. and Bristol Myers Squibb. Mr. Morton holds a Master of Business Administration degree from Durham University and is an Honorary Professor at Durham University Business School. Mr. Morton also holds a Bachelor of Science degree in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme. Mr. Morton was honored in 2016 by Her Majesty the Queen and was awarded a CBE (Commander of the Most Excellent Order of the British Empire) for services to the Healthcare Industry.